A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2002
10/23/2002	EP1250356A2 POTASSIUM CHANNEL MUTANTS OF THE i SACCHAROMYCES CEREVISIAE /i YEAST AND THE USE THEREOF FOR THE SCREENING OF EUKARYOTIC POTASSIUM CHANNELS
10/23/2002	EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity
10/23/2002	EP1250347A1 Antisense modulation of akt-3 expression
10/23/2002	EP1250340A1 Methods and compounds for inhibiting mrp1
10/23/2002	EP1250338A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors
10/23/2002	EP1250337A1 Substituted homopiperidinyl benzimidazole analogues as fundic relaxants
10/23/2002	EP1250332A1 Inhibitors of interleukin 5 gene expression
10/23/2002	EP1250326A2 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250321A1 Glyburide composition
10/23/2002	EP1250313A1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250152A1 Hyaluronic acid in the treatment of cancer
10/23/2002	EP1250151A1 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
10/23/2002	EP1250146A2 Use of neurotoxins for treating diabetes
10/23/2002	EP1250140A2 Combinations of a receptor tyrosine kinase inhibitor with alpha1-acidic glycoprotein binding compound
10/23/2002	EP1250139A1 Product for treating gynecomastia
10/23/2002	EP1250137A2 Jak/stat pathway inhibitors and the uses thereof
10/23/2002	EP1250132A1 Ibuprofen containing active agent preparation
10/23/2002	EP1250128A2 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
10/23/2002	EP1250126A2 Transepithelial delivery of glp-1 derivatives
10/23/2002	EP1196384A4 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
10/23/2002	EP1091959B1 Novel pyrrolo-(3,4-b)quinoline derivatives, method for the production and use thereof as a medicament
10/23/2002	EP1086095B1 Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
10/23/2002	EP1073664B1 (alpha-aminophosphino) peptidesderivative and compositions containing same
10/23/2002	EP1066297B1 Phosphinic acid derivatives
10/23/2002	EP1061943B1 Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
10/23/2002	EP1000067B1 Thiazolobenzoheterocycles, preparation and medicines containing same
10/23/2002	EP0925303B1 Phosphinic acid amides as matrix metalloprotease inhibitors
10/23/2002	EP0923561B1 Heterocyclic metalloprotease inhibitors
10/23/2002	EP0894089B1 Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP0869947B1 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/23/2002	EP0858345B1 Use of muteins of wild-type cytokines as immunogens
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0783499B1 Benzofuran derivatives as tachykinin antagonists
10/23/2002	EP0772446B1 Anti-adhesion agent
10/23/2002	EP0723552B1 Oligopeptides derived from c-reactive protein fragments
10/23/2002	CN1376164A Gcsf缀合物 Gcsf conjugates
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376154A Piperidine derivatives as serotonine reuptake inhibitors
10/23/2002	CN1376150A Drug compositions exhibiting thrombo poietin agonism
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376143A Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient
10/23/2002	CN1376068A Echinacea supplement and method of manufacture
10/23/2002	CN1376065A Compositions having improved stability
10/23/2002	CN1376063A Cyclic amine CCR3 antagonisis
10/23/2002	CN1376058A Oral controlled release formulations
10/23/2002	CN1376056A Liposome-entrapped DNA oral vaccines
10/23/2002	CN1375494A Iso-indolo-indolone compound, their preparation methods and drug compositions comprising the same
10/23/2002	CN1375490A Novel indeno indolone compound, its preparation method and drug composition comprising the same
10/23/2002	CN1375335A Beta signal transduction blocker as a transforming growth factor and its use
10/23/2002	CN1375329A Composite medicine for treating lymph node tumescence and its usage
10/23/2002	CN1375323A Medicine powder for six domestic animals to invigorate kidney and become plump
10/23/2002	CN1375314A Fermented soybean extracted liquid and composite medicine containing the said liquid
10/23/2002	CN1375303A Ointment for dredging meridian passage and expelling wind-evil
10/23/2002	CN1375296A Coma treating composition medicine and its usage
10/23/2002	CN1093133C 10,13,15-trioxyheterotricyclo [9,2,1,1,9,6]-pentadecanone derivatives, its preparing method and medicine containing it
10/23/2002	CN1093130C Substituted pyrido 6,6-bicyclic derivatives
10/23/2002	CN1093128C Process for preparing eprosartan
10/23/2002	CN1093127C 哌嗪衍生物 Piperazine derivatives
10/23/2002	CN1093125C Sulfamide-metalloprotease inhibitors
10/23/2002	CN1093123C Aralkyl and aralkylidene heterocyclic lactams and imides
10/23/2002	CN1093122C Piperazine derivatives as 5-HTIA antagonists
10/23/2002	CN1092990C Modulation of cell proliferation and wound healing
10/23/2002	CN1092960C Pharmaceutical composition comprising proteinase inhibitor and monoglyceride
10/23/2002	CA2383115A1 Use of an effective amount of at least one ion chelating agent to enhance the tolerance level of sensitive or intolerant skin
10/23/2002	CA2381630A1 Method for preventing dyskinesias
10/22/2002	US6469144 Apo-2li (apo-2 ligand inhibitor, related to apoptosis) monoclonal antibodies
10/22/2002	US6469067 For treatment of livestock for parasites; comprises 1-(4-chloro-3-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenyl)-3-(2,6-difluorobenzoyl)urea and one of: ivermectin, doramectin, moxidectin and selamectin
10/22/2002	US6469064 Treating depression and affective disorders, such as obsessive compulsive disorder in a patient by administering to the patient an effective amount of flavoxamine ester derivatives
10/22/2002	US6469058 For the treatment of nonsmall cell lung cancer
10/22/2002	US6469055 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469043 Antiangiogenic agent with antitumor, antimetastatic properties which shows high safety
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469029 Azacycloalkanone serine protease inhibitors
10/22/2002	US6469025 For the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role; inhibiting the binding of alpha 4 integrins to their ligands
10/22/2002	US6469021 Non-peptide antagonists of GLP-1 receptor and methods of use
10/22/2002	US6469016 Treatment of female sexual dysfunction using phosphodiesterase inhibitors
10/22/2002	US6469013 Therapeutic compounds
10/22/2002	US6469011 Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
10/22/2002	US6469007 P-substituted-n-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-n-pyridin-2-yl-benzamide,
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6469002 Compounds which modulate chemokine receptor activity and are useful in treatment of inflammatory diseases
10/22/2002	US6469000 1,3-diheterocyclic metalloprotease inhibitors
10/22/2002	US6468983 RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/22/2002	US6468980 Composition comprising cancer chemotherapeutic agent and potentiating agent selected from group consisting of vitamin c metabolites or ascorbic acid-derived furanones
10/22/2002	US6468977 Compounds useful in treatment treatment of disorder and/or disease caused by activity of enzymes such as human rhinovirus 3c protease, transglutaminase and cathepsins
10/22/2002	US6468975 Glucocorticoid receptor antagonists that are preferably liver selective and are useful in treatment of diabetes
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468964 Administering to human or animal active agent capable of preventing or controlling acid and endotoxin accumulation in gastrointestinal tract, selected from antibiotics, enzymes, clays, probiotics, compounds which slow rate of passage
10/22/2002	US6468794 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
10/22/2002	US6468533 Polyclonal or monoclonal antibody that inhibits high mobility group 1 protein mediated activation of inflammatory cytokine cascade; sepsis
10/22/2002	US6468502 Paramagnetic macromolecules with higher proton relaxivity; lower dosage and increased signal intensity; detecting vascular diseases; differentiating tissue blood supply levels; distinguishing myocardial infarction from ischemia

1 ... 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 ... 1564